. "risperdone"@en . . . . . . . . . . . . . . . . . . . . . . "Risperdal"@en . . . . . . . . . "Well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution."@en . . "Sequinan"@en . "Risperidona"@en . "# Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16004936 # Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 Jan;29(1):64-73. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19113797 # Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15907153 # Kemp DE, Canan F, Goldstein BI, McIntyre RS: Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther. 2009 Jun;26(6):588-99. Epub 2009 Jun 26. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19562274 # Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006 Jun;26(6):748-58. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16716128 # Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18537577 # Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3(6):356-61. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14610521"@en . "Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is used primarily in the management of schizophrenia, inappropriate behavior in severe dementia and manic episodes associated with bipolar I disorder. Risperidone is effective for treating the positive and negative symptoms of schizophrenia owing to its affinity for its \u201Cloose\u201D binding affinity for dopamine D2 receptors and additional 5-HT antagonism compared to first generation antipsychotics, which are strong, non-specific dopamine D2 receptor antagonists."@en . "106266-06-2"@en . . "Symptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD₅₀=82.1mg/kg (orally in mice). "@en . . "Risperidone"@en . . "Risperidone is extensively metabolized in the liver.In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects."@en . . . . . . . . . . . . . . . . . "Risperidone, ~88% bound; 9-hydroxyrisperidone, ~77% bound. "@en . . . . . . . . . . . . . . "Risperidonum"@en . . . . . . . . . . . . . . . . . . . . . . . "Rispolept"@en . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Risperidone.htm"@en . . . . . . . . . "Blockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT₂ receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT₂ antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors."@en . "Humans and other mammals"@en . . . . . "For the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropriate behavior due to aggression and/or psychosis in patients with severe dementia. "@en . . "* 1 to 2 L/kg"@en . . . . . . . . . . . . "20-24 hours"@en . "approved"@en . . . . . " "@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Rispolin"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Risperin"@en . . . . . . . . . . . . . . . "investigational"@en . . . . . . . . . . . . . . . . . . . . . .